Literature DB >> 19013327

Antiretroviral nephrotoxicities.

Mohamed G Atta1, Gilbert Deray, Gregory M Lucas.   

Abstract

With the introduction of combination antiretroviral therapy, there have been substantial declines in both morbidity and mortality associated with human immunodeficiency virus (HIV)-1 infection. However, data increasingly indicate that HIV-1-infected individuals are faced with accelerated rates of chronic diseases that afflict the general population such as diabetes mellitus, hypertension, and dyslipidemia, as well as cardiovascular, liver, and kidney diseases. Furthermore, this population is exposed to a variety of adverse effects from long-term use of antiretroviral medications, which may cause clinically important renal toxicities. However, it often is challenging to distinguish antiretroviral-related renal toxicity from either direct effects of HIV-1 on the kidney or from a multitude of non-HIV-related kidney diseases. A timely and coordinated effort by the HIV primary provider and a nephrologist is likely to facilitate the evaluation of HIV-1-infected patients with new kidney problems.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19013327     DOI: 10.1016/j.semnephrol.2008.08.009

Source DB:  PubMed          Journal:  Semin Nephrol        ISSN: 0270-9295            Impact factor:   5.299


  10 in total

1.  HIV and HCV Medications in End-Stage Renal Disease.

Authors:  Keiko I Greenberg; Mark A Perazella; Mohamed G Atta
Journal:  Semin Dial       Date:  2015-04-06       Impact factor: 3.455

Review 2.  Clinical Pharmacology in HIV Therapy.

Authors:  Mohamed G Atta; Sophie De Seigneux; Gregory M Lucas
Journal:  Clin J Am Soc Nephrol       Date:  2018-05-29       Impact factor: 8.237

3.  Tubulointerstitial nephropathies in HIV-infected patients over the past 15 years: a clinico-pathological study.

Authors:  Mohamad Zaidan; François-Xavier Lescure; Isabelle Brochériou; Sarah Dettwiler; Jean-Baptiste Guiard-Schmid; Jérôme Pacanowski; Eric Rondeau; Gilles Pialoux; Pierre-Marie Girard; Pierre Ronco; Emmanuelle Plaisier
Journal:  Clin J Am Soc Nephrol       Date:  2013-02-21       Impact factor: 8.237

4.  Non-productive HIV-1 infection of human glomerular and urinary podocytes.

Authors:  Atanu K Khatua; Harry E Taylor; James E K Hildreth; Waldemar Popik
Journal:  Virology       Date:  2010-12-05       Impact factor: 3.616

5.  Long-term renal safety of tenofovir disoproxil fumarate in vertically HIV-infected children, adolescents and young adults: a 60-month follow-up study.

Authors:  Alessandra Viganò; Giorgio Bedogni; Valeria Manfredini; Vania Giacomet; Chiara Cerini; Francesca di Nello; Francesca Penagini; Cristiana Caprio; Gian Vincenzo Zuccotti
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

6.  Prevalence of proteinuria and elevated serum cystatin C among HIV-Infected Adolescents in the Reaching for Excellence in Adolescent Care and Health (REACH) study.

Authors:  Kristal J Aaron; Mirjam-Colette Kempf; Robert H Christenson; Craig M Wilson; Paul Muntner; Sadeep Shrestha
Journal:  J Acquir Immune Defic Syndr       Date:  2012-12-01       Impact factor: 3.731

7.  Nephrotoxicity of HAART.

Authors:  Robert Kalyesubula; Mark A Perazella
Journal:  AIDS Res Treat       Date:  2011-08-15

8.  Screening for decreased glomerular filtration rate and associated risk factors in a cohort of HIV-infected patients in a middle-income country.

Authors:  Patrícia Santiago; Beatriz Grinsztejn; Ruth Khalili Friedman; Cynthia B Cunha; Lara Esteves Coelho; Paula Mendes Luz; Albanita Viana de Oliveira; Ronaldo Ismério Moreira; Sandra W Cardoso; Valdilea G Veloso; José H Rocco Suassuna
Journal:  PLoS One       Date:  2014-04-03       Impact factor: 3.240

9.  Tenofovir alafenamide nephrotoxicity in an HIV-positive patient: A case report.

Authors:  Tessa K Novick; Michael J Choi; Avi Z Rosenberg; Blaithin A McMahon; Derek Fine; Mohamed G Atta
Journal:  Medicine (Baltimore)       Date:  2017-09       Impact factor: 1.889

Review 10.  Aging with HIV: a practical review.

Authors:  Sandra Wagner Cardoso; Thiago Silva Torres; Marilia Santini-Oliveira; Luana Monteiro Spindola Marins; Valdiléa Gonçalves Veloso; Beatriz Grinsztejn
Journal:  Braz J Infect Dis       Date:  2013-05-25       Impact factor: 3.257

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.